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Abstract
Background: In early-stage Non-Small Cell Lung Cancer (NSCLC) patients, little is known about how to measure
patient participation in Shared-Decision Making (SDM). We examined the psychometric properties and clinical
acceptability of the Decision Self-Efficacy scale (DSE) in a cohort of patients undergoing to Stereotactic Ablative
Radiotherapy (SABR) or Video-assisted Thoracoscopic Surgery (VATS) to capture patient involvement in treatment
decisions.
Methods: In the context of a prospective longitudinal study (Life after Lung Cancer-LiLAC) involving 244 patients
with early-stage NSCLC, 158 (64.7%) patients completed the DSE either on paper or electronically online prior to
treatment with SABR or VATS pulmonary resection. DSE psychometric properties were examined using: principal
components analysis of item properties and internal structure, and internal construct validity; we also performed a
sensitivity analysis according to Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender, age
and treatment received (VATS or SABR) difference.
Results: Exploratory factor analysis using polychoric correlations substantiated that the 11 item DSE is one scale
accounting for 81% of the variance. We calculated a value of 0.96 for Cronbach’s alpha for the total DSE score.
DSE scores did not differ by gender (p = 0.37), between the two treatment groups (p = 0.09) and between younger
and older patients (p = 0.4). However, patients with an ECOG PS > 1 have a DSE mean of 73.8 (SD 26) compared to
patients with a PS 0–1 who have a DSE mean of 85.8 (SD 20.3 p = 0.002).
Conclusion: Findings provide preliminary evidence for the reliability and validity of the DSE questionnaire in this
population. However, future studies are warranted to identify the most appropriate SDM tool for clinical practice in
the lung cancer treatment field.
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Introduction
The most effective treatment options for curative lung
cancer are video assisted thoracoscopic (VATS) resection
or stereotactic ablative body radiotherapy (SABR) for pa-
tients unfit for surgery. The treatment effectiveness is
evaluated on survival data [1, 2] and presently there is lit-
tle information about the effects of these treatments on
patients’ quality of life (QoL) [3, 4]. About 44% of patients
diagnosed with lung cancer are aged 75 and over [5] and
commonly have multiple comorbidities with 54% present-
ing with three or more [6] reducing their eligibility for sur-
gery [6, 7]. This makes the patient’s decision to proceed
with one of these treatments more complex, especially for
those patients at higher medical risk.
Although current treatment guidelines do not recom-
mend SABR as first-line treatment for Non-Small Cell
Lung Cancer (NSCLC) moderate risk patients [1], multiple
observational studies have suggested therapeutic equipoise
exists between SABR and surgery in those patients with
multiple comorbidities [8, 9]. The lack of long term QoL
data from these two treatments has highlighted the import-
ance of understanding whether a truly informed, shared
treatment decision between patients and clinicians can be
made. The quality of sharing this decision is highly
dependent on the interaction in the patient-physician con-
sultation, and the type of the information given.
It is unclear what needs patients have when faced with
a choice between treatment options as often, improved
knowledge about surgery does not necessarily translate
into a more proactive attitude towards decision-making
in the lung cancer setting [10]. It has been reported in
lung cancer surgery, that many patients may wish to
defer decisions about treatment to their medical team
[10]. On the other hand, physicians have to be confident
they have the skills to best support patients in a shared-
decision making. In a Dutch survey, 30% of surgeons
stated they are not properly trained to implement SDM
in clinical practice [11]. Recent research in this field also
confirmed that as result of the lack in standardized ap-
proach and deep understanding of SDM process, only
28.9% patients have been offered both treatment options
for treatment of early-stage NSCLC [12].
Working towards patient and physician shared
decision-making (SDM) for treatment of curative NSCL
C in clinical practice will require the development of
guidelines and their integration into existing decisional
algorithms. The last two decades have witnessed an in-
creasing number of trials investigating the overall lack of
concordance between physician and patient perceptions
of the decisional context in many clinical areas including
lung cancer management. The majority of these trials
have shown that concerns and treatment strategies were
insufficiently discussed between the patients and physi-
cians [12, 13].
Over the last 30 years, a number of measures have been
developed to assess components of patient informed,
values-based choices [14]. While, many different measures
are available, the degree to which these measures are fully
validated varies significantly. Currently, there is paucity of
evidence assessing the views of patients with stage I NSCL
C on aspects of shared decision-making (SDM).
To support proactively patients with cancer making
decisions with physicians [14], a first step is to explore
factors associated with patient confidence in involve-
ment in the SDM process. Self-efficacy is a psychological
construct referring to an individual’s judgment of the
confidence to carry out a specific task in order to pro-
duce a desired outcome [12]. Furthermore, studies have
shown self-efficacy has direct and indirect effect on QoL
in patients with resected lung cancer [15].
Our aim was to assess the psychometric validity and
sensitivity of the decision self-efficacy scale (DSE) in a
cohort of early stage NSCLC patients undergoing SABR
or VATS anatomical lung resection.
Methods
Design and sample
This design is a secondary analysis of data from a pro-
spective longitudinal study of patients offered Stereotac-
tic ablative radiotherapy (SABR) or Video-Assisted
Thoracoscopic Surgery (VATS) for NSCLC in a large
urban regional cancer centre (UK) between March 2017
to March 2018.
This study assesses the utility of a patient reported meas-
ure of decision making confidence carried out as part of the
Life after Lung Cancer (LiLAC) study [4]. LiLAC used vali-
dated Patient-reported outcome measures (PROMs) to de-
scribe the trajectory of Quality of Life (QoL) following
VATS or SABR treatment. This study received ethical ap-
proval from NRES Yorkshire and the Humber- Leeds East
Research Ethics Committee (REC Ref: 16/YH/0407), and is
registered in Clinicaltrial.gov database.
Procedures
All participants completed (online or on paper) a set of
questionnaires before their treatment (between 1 to 20
days before) to capture their preoperative QoL and Deci-
sion efficacy. Patients at this point have been already al-
located to a treatment group as per multi-disciplinary
team meeting (MDT) decision.
The Decision Self-Efficacy Scale (DSE) measures self-
confidence or belief in one’s ability to make informed de-
cisions and participate in shared decision making with
health professionals [16]. It is a 11-item instrument with a
five-point response scale ranging from 0 (not at all
confident) to 4 (very confident). An example question is: ‘I
understand the information enough to be able to make a
choice’). The psychometric properties report a Cronbach
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alpha coefficient of 0.92, and the scale has been shown to
be correlated with select subscales of the Decisional Con-
flict scale (DSC) [i.e., feeling informed (0.47) and sup-
ported (0.45) sub-scales] [17]. Scores are linearly
transformed: score of 0 means ‘extremely low self-efficacy’
and a score of 100 means ‘extremely high self-efficacy’.
Missing values are imputed using a single imputation
method as recommended if the amount of missing data is
below 10% [18]. Specifically, as DSE is a single scale, we
follow the recommended approach used by most com-
monly used PROMs [19]: if at least half of the items from
the scale have been answered, it is assumed that the miss-
ing items have values equal to the average of those items
that are present for the respondent.
The following baseline demographic and clinical vari-
ables were collected: age, sex, forced expiratory volume
in 1 s (FEV1) expressed in percentage of predicted value,
Eastern Cooperative Oncology Group Performance Sta-
tus (ECOG PS), diffusing capacity of the lung for carbon
monoxide (DLCO) expressed in percentage of predicted
value, treatment type and smoking habit. Performance
status represents a holistic assessment of a patient’s
functional capacity, which reflects the additive physical,
physiological and psychological effects of the disease
process. The two most commonly used measurement in-
struments to assess performance status or fitness for
cancer treatments include the Eastern Cooperative On-
cology Group Performance Status (ECOG PS) [20] and
Karnofsky Performance Status (KPS) [21] scales. Al-
though the two scales have been shown to be inter-
changeable, we have used the ECOG scale is for its
simplicity and interobserver reproducibility [22, 23].
ECOG uses 5 points score to assess PS and is considered
simple tool to use in daily clinical practice [20].
Analysis
The study sample demographic and clinical characteris-
tics were summarised using descriptive statistics.
An exploratory factor analysis (EFA) was performed to
examine the underlying factors of the DSE. The minimum
recommended sample size to conduct a EFA is 100 [24].
An exploratory (principal axis) factor analysis was con-
ducted on the 11 DSE items from N = 158 cases items using
IBM SPSS version 24. In addition to the total variance ex-
plained, the scree plot, eigenvalues and parallel analysis were
assessed to verify the factor structure of DSE in this cohort.
The factor analysis was performed using SPSS (IBM) Version
24 and for further exploration with parallel analysis and poly-
choric correlations ‘FACTOR’ Version 10.10.03 (Rovira i Vir-
gili University, Spain). We used STATA 15.0 (Stata Corp.,
College Station, TX, USA) statistical software to analyse (1)
descriptive statistics, (2) floor and ceiling effects (% scores at
the minimum and maximum values), and (3) internal reli-
ability (Cronbach’s alpha, corrected item-total correlations).
Although in the development studies Bunn [25] did
not specify criteria for defining floor and ceiling effects,
we employed the widely used N 15% of minimum/max-
imum scores cut-off [26]. Following convention, we con-
sidered Cronbach’s alpha’s ≥ 0.70 to indicate acceptable
internal consistency [27]. Feasibility was also assessed, in
terms of proportion of missing data (“prefer not to an-
swer” responses for the dataset overall and per item).
We considered that < 5% missing data overall was ac-
ceptable, although we acknowledge there is no estab-
lished consensus on this issue, with recommended
criterion values ranging from 5 to 20% [28].
For highly related constructs, moderate to strong asso-
ciations (r ~ +/− 0.40 to 0.80) between these determi-
nants and the factors of the DSE were expected [29].
Sensitivity of the module was assessed by means of
known group differences according to the Performance Sta-
tus, gender, age and treatment received (VATS or SABR).
As all the DSE variables were not normally distributed,




A total of 244 patients consented to the study of which
158 (64.7%) returned the Decision Self-Efficacy Scale at
baseline. Of these, 73 patients were treated using SABR,
and 85 had VATS. We did not find any baseline differ-
ence between patients who completed the DSE (n = 158)
and those who didn’t (N = 86) in terms of age (p:0.17),
gender (p = 0.34) and PS > 1(p = 0.23). A table including
characteristics of the whole cohort of patients included
into the Lilac study are provided in Supplementary File 1.
Patients treated with SABR were older, with more co-
morbidities, lower FEV1 and DLCO values and higher
PS. These differences were, however expected as the
SABR treatment was indicated to those patients who
were not physiologically fit for surgery.
The baseline clinical characteristics of the participants
included in this study are in listed in Table 1.
Mean value of the DSE was 81.7 (SD 23). In the Surgi-
cal group the mean score was 83.6 (SD 22.9) and in the
SABR group was 79.5 (SD 23). DSE is the main score
representing the overall efficacy in making the decision.
Exploratory factor analysis
First stage
An EFA analysis initially using Pearson’s correlations was
conducted on the 11 items using principal axis factoring
and an oblique (direct oblimin) as it was expected that the
factors would not be independent. The Kaiser-Meyer-
Olkin (KMO) measure verified sampling adequacy for the
analysis (KMO= .91) well above the minimum criterion of
.50, in addition all KMO values for individual items were ≥
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.88 and Bartlett’s test of sphericity was also significant at
p < .001. An initial analysis was run and factors retained
using three conventions, i) Kaiser’s criterion of eigenvalues
over 1, ii) inflections in the scree plot and ii) parallel ana-
lysis [30]. Two factors had Eigen values over Kaisers criterion
of 1 (7.91 and 1.02 respectively) and the scree plot depicted
two inflections confirming Eigen values over 1. However, to
further explore whether second factor (just over Kaisers
threshold > 1) was not due to chance, a parallel analysis was
performed using a permutation of the raw data [31]. This ana-
lysis strongly suggested rejection of the second factor with 95
percentiles of random % of variance (18.28) generated which
is greater than the real data % of variance (6.78).
Secondary
To further explore the DSE we used principal axis factoring
with polychoric correlations and the Kaiser-Meyer-Olkin
(KMO) was again adequate (KMO= .60) and Bartlett’s test
of sphericity was also significant at p < .001. This substanti-
ated that the DSE is a one factor scale with one Eigen value
identified over the threshold explaining 81% of the variance
(Table 2), therefore, a factor loading plot was not computed.
Construct validity
The decision self-efficacy scale performed well in terms of
psychometrics in this sample (Table 3): we calculated a
value of 0.96 for Cronbach’s alpha for the total DSE score.
The overall amount of missing data was 1.5% of the data-
set which is in line with the developer’s data [25]. How-
ever, a notable ceiling effects with a significant proportion
scoring substantially over the whole DSE (Table 3).
The items correlated significantly at p = 0.001. A de-
terminant value of 2.09E-006 (above the necessary value
of 0.00001) revealed that the level of collinearity would
not be detrimental to the analysis therefore, no items
were removed. The polychoric correlation matrix is pro-
vided in the Supplementary File 2.
Known-group differences
Group comparisons revealed no significant mean differ-
ences between the two treatment groups in terms of
overall self-efficacy score (DSE): SABR 79.5, Surgery 83.6
(p = 0.09). There were no statistical differences between
the two groups for each of the eleven items either
(Table 4).
Patients with the ECOG PS > 1, less fit, reported lower
self-efficacy in making their decision during the preopera-
tive period. Indeed, patients with PS > 1 have a DSE mean
of 73.8 (SD 26) compared to patients with a PS 0–1 who
have a DSE mean of 85.8 (SD 20.3 p = 0.0024).
No statistically significant differences between DSE
scores for men and women were evident (p = 0.37). Male
patients had a mean DSE value of 84.0 (SD 21.3) and fe-
male of 79.9 (SD 24.2).
Similarly, when comparing DSE among younger and
older people (using the cut-off above and below the me-
dian value of 72 years) no statistically significant differ-
ences were found (p = 0.4). In particular, older people >
Table 1 Baseline demographic and clinical characteristics of participants N = 158
Variable All patients with DSE (n = 158) SABR (n = 73) Surgery (n = 85)
Treatment (surgery, %) 85 (53.8)
Gender (male, %) 69 (43.6) 26 (35.6) 43 (50.5)
Age (years, SD) 72.4 (8.6) 74.5 (9.3) 70.5 (7.5)
Comorbidity (yes, %) 135 (85.4) 67 (91.7) 68 (80)
FEV1% (SD) 83.5 (25.1) 75.5 (27.4) 89.2 (21.8)
DLCO% (SD) 77.6 (22.2) 69.6 (22.8) 83.5 (19.9)
Currently smoking (n, %) 34 (22.6%) 19 (27.1) 15 (18.7)
PS > 1 (n, %) 104 (62.4) 39 (53.4) 15 (17.6)
DSE (Mean, SD) 81.7 (23) 79.5 (23) 83.6 (22.9)
Results are expressed as mean and standard deviation (SD) for numeric variables and as count and percentages for categorical variables. FEV1: forced expiratory
volume in 1 second; diffusing capacity of the lung for carbon monoxide (DLCO) expressed in percentage of predicted value, Eastern Cooperative Oncology Group
Performance Status (PS).
Table 2 Extracted eigen values and % of variance after
polychoric correlations (N = 158)
Eigen value Total % of Variance Cumulative %
1 9.00 81.00 81.00
2 0.74 7.00 88.00
3 0.40 3.00
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72 years had a DSE mean of 82.5 (SD 23.7) and younger
people < 72 years 81 (SD 22.6).
Discussion
We aimed to explore the psychometric properties of the
DSE in a cohort of patients undergoing VATS resection or
SABR therapy for NSCLC. Our findings suggest the DSE is
valid: the 11-item measure has good internal consistency (α
of 0.96), and is one scale explaining 81% of the variance.
The developers’ recommendation for one scale is confirmed
by the observed high internal consistency in our study,
however, we would recommend further exploration of the
DSE in other cancer populations.
The observed significant ceiling effect (over 15% of re-
sponses) should be noted. No data about ceiling or floor effect
have been published for the DSE. However, a recent system-
atic review of existing measures of self-efficacy in cancer pa-
tients, reported that these psychometric properties were not
often assessed [32]. The timing of assessment in our popula-
tion (after the decision) may have affected the results.
Almost 70% of the sample completed the decision self-
efficacy scale demonstrating that the collection of this
data is possible in this population. Furthermore, the
overall proportion of missing data was low (1.5%), indi-
cating that DSE was acceptable to patients.
There was no difference in efficacy with decision mak-
ing by treatment type in this study. Patients with poor
clinical performance status were more likely to be less
confident in making their decision for treatment. We
know patients who have a worse PS and limited functional
capacity tend to have more difficulty tolerating rigorous
NSCLC cancer treatments, i.e. they have less favourable
outcomes than fitter patients regardless of treatment type
[33, 34]. One explanation can be that regardless of the
treatment type when patients are less independent physic-
ally (as in those with higher PS score), they have more
conflict or difficulty deciding about the best treatment to
meet their needs. In addition, performance status and
NSCLC cancer stage were significantly more influential
than biological age when recommending treatments [35].
In this sense, physicians may tend to involve patients with
a higher PS score less in the decision-making process, pre-
sumably with concerns about higher expected morbidity
and mortality. In those cases, patients may perceive simi-
larly less confidence in making that decision which is
more “physician-driven”. Another possible explanation
can be related to the fact that patients more compromised
were never involved in discussions about possible treat-
ment alternative i.e. surgery: this may have influenced
their efficacy in making the treatment decision as their
opinion may have not played a role at all in all the course
of the decision-making process.
The decision efficacy scale has previously been evalu-
ated in patient populations referring to patient’s making
decision regarding immunizations, screening, hormone
replacement therapy, blood pression medications adher-
ence [36–38] suggesting a good understanding and ap-
plicability of this questionnaire in field where difficult
decisions need to be taken [17]. For NSCLC patients it
would be useful to investigate if they, not only have the
self-efficacy but the ability to ask questions and clearly
express their values and prediction of outcomes.
Table 3 Descriptive statistics, floor and ceiling effects and internal reliability for the DSE
N Mean (SD) Floor effect (%min score) Ceiling effect (%max score)
DSE 158 81.7 23 0.63% 32.9%
Table 4 Total DSE and DSE individual questions scores in SABR and Surgical groups
Item Surgery (n = 85)
Mean (SD)
SABR (n = 73)
Mean (SD)
p value
DSE total score 83.6 (22.9) 79.5 (23.1) 0.09
1. Get the facts about medication choices available to me 85.2 (23.5) 80.4 (26.1) 0.13
2. Get the facts about the benefits of each choice 83.5 (26.0) 79.1 (26.0) 0.10
3. Get the facts about the benefits and risks of each choice 84.1 (25.8) 80.1 (27.3) 0.21
4. Understand the information enough to be able to make a choice 84.4 (26.1) 82.8 (24.6) 0.33
5. Ask questions without feeling dumb 84.4 (30.8) 79.7 (30.8) 0.34
6. Express my concerns about each choice 83.5 (26.8) 78.0 (30.0) 0.16
7. Ask for advice 87.0 (26.8) 82.8 (26.3) 0.11
8. Figure out the choice that best suits me 84.1 (23.7) 79.1 (28.8) 0.35
9. Handle unwanted pressure from others in making my choice 80.8 (29.2) 77.3 (30.6) 0.51
10. Let the clinic team know what’s best for me 83.8 (22.0) 77.7 (31.0) 0.50
11. Delay my decision if I feel I need more time 79.1 (31.5) 76.7 (31.5) 0.88
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O’Connor developed within the same conceptual
framework of the DSE a 16-item Decisional Conflict
Scale rated on a Likert scale measuring the uncertainty
in choosing options, modifiable factors contributing to
uncertainty (information, values and social support) [17].
In situations where the evidence available is not clearly
defined and the long-term benefits are still undeter-
mined (as with SABR Vs VATS), the understanding of
conflict in difficult decisions may be more relevant to
help identifying patient’s needs and possibly develop tai-
lored decision aids.
The implementation of a decision aid in the field of
early stage NSCLC has the potential also to streamline the
pre-treatment pathway and reducing the referral to a sec-
ond speciality opinion in these patients care. The decision
conflict scale could be clinically more applicable to the
conflictual choice between surgery and SABR especially
for those borderline patients, where there is a clear equi-
poise in terms of risks and benefit, an observation
highlighted in the SABRTooth trial [39]. In high risk pa-
tients where the surgery has not been completely excluded
by objective parameters, the decision should be tailored
and supported by the medical team but also with the use
of validated decision aids, as successfully demonstrated in
other specialities [40]. It would also be important to inves-
tigate and measure the involvement in decision and the
ability to access and understand information [41]. How-
ever, we must be aware that a good decision often doesn’t
correspond to a good outcome: indicators of good deci-
sion making may include reduced uncertainty, improved
knowledge, more realistic expectations, improved clarity
of values and value congruence with the decision; reduced
decision delay; improved adherence to the decision, and
efficacy [17, 42]. Understanding the latter, can have crucial
clinical implications in the development of a decision aid
and ultimately help people considering their options and
making the best decision for themselves.
Limitations
The return rate of a 67% is reasonable for self-report
questionnaires, but there may be a possibility those who
did not complete the questionnaire had different experi-
ences which could impact on the findings. Further inves-
tigation of its psychometric properties in samples which
include a wider group of patients is advised, and
methods to enable further validation data.
The study had a relatively small sample size, and was
performed in a single centre. Certainly, it seems that the
processes to choose between treatment types in NSCLC
cancer are similar, suggesting the same type of informa-
tion about the risks and benefits and long-term conse-
quences of both treatments should be presented equally
by clinicians to support informed choice. Alternatively, it
may be that this questionnaire is not as sensitive to the
differences between the different types of choices as
other measures, e.g. decisional conflict scale. Certainly,
patients found it difficult to make a treatment choice, re-
gardless of treatment type, suggesting a decision aid
might be helpful for patients to reach a decision with
greater confidence. However, the questionnaire has not
up till now been tested in a cancer population. Previ-
ously the DSE had been utilised with menopausal
woman and psychiatric patients [16, 19], thus limiting
the comparability of our findings.
Another limiting factor of our study design is that we
collected the questionnaires after patients made their
final decision; it may be that there are more patients
who do not feel involved in their decision making earlier
in the treatment pathways. This data collection method
may, in part, explain the high ceiling effects as people’s
views and exposure to further information will change
from diagnosis to after treatment.
Conclusions
We demonstrated that the collection of decision efficacy
questionnaire in a population of NSCLC cancer patients
facing difficult decision is feasible. We provided evidence
for the validity of the DSE as a11-item measure compris-
ing one scale. Our results demonstrated that the DSE
questionnaire discriminates between the low and high
PS of patients. This confirms the importance to identify
those patient subgroups which will benefit from pro-
grammes aimed to improve their participation in treat-
ment decision-making contexts.
The conflict, more than the social and emotional com-
ponent, of the difficult-decision making may be more
relevant when evaluating the routine data collection in
complex clinical area like this one [43]. This may help
identify people with greater need of help and thus enable
specific support in making decisions and will help in the
future tailoring of specific decision aids.
Our study findings may also inform future investiga-
tions around decision making within complex care and
the resources required to reliably collect information on
SDM process in clinical practice.
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